Background: The one-carbon metabolism pathway is vital in maintaining tissue homeostasis by driving the critical reactions of folate and methionine cycles. A myriad of genetic and epigenetic events mark the rate of reactions in a tissue-specific manner. Integration of these to predict and provide personalized health management requires robust computational tools that can process multiomics data. The DNA sequences that may determine the chain of biological events and the endpoint reactions within one-carbon metabolism genes remain to be comprehensively recorded. Hence, we designed the one-carbon metabolism database (1-CMDb) as a platform to interrogate its association with a host of human disorders. Methods: DNA sequence and network information of a total of 48 genes were extracted from a literature survey and KEGG pathway that are involved in the one-carbon folate-mediated pathway. The information generated, collected, and compiled for all these genes from the UCSC genome browser included the single nucleotide polymorphisms (SNPs), CpGs, copy number variations (CNVs), and miRNAs, and a comprehensive database was created. Furthermore, a significant correlation analysis was performed for SNPs in the pathway genes. Results: Detailed data of SNPs, CNVs, CpG islands, and miRNAs for 48 folate pathway genes were compiled. The SNPs in CNVs (9670), CpGs (984), and miRNAs (14) were also compiled for all pathway genes. The SIFT score, the prediction and PolyPhen score, as well as the prediction for each of the SNPs were tabulated and represented for folate pathway genes. Also included in the database for folate pathway genes were the links to 124 various phenotypes and disease associations as reported in the literature and from publicly available information. Conclusion: A comprehensive database was generated consisting of genomic elements within and among SNPs, CNVs, CpGs, and miRNAs of one-carbon metabolism pathways to facilitate (a) single source of information and (b) integration into large-genome scale network analysis to be developed in the future by the scientific community. The database can be accessed at http://slsdb.manipal.edu/ocm/.

Keywords:
Database, One-carbon pathway, Single nucleotide polymorphisms, Copy number variations, CpGs, miRNAs
1.
Hood L, Health JR, Phelps ME, Lin B: Systems biology and new technologies enable predictive and preventative medicine. Science 2004;306:640-643.
2.
The 1000 Genome Project Consortium: a map of human genome variation from population-scale sequencing. Nature 2010;467:1061-1073.
3.
Locasale JW: Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer 2013;13:572-583.
4.
Mehrmohamadi M, Liu X, Shestov AA, Locasale JW: Characterization of the usage of the serine metabolic network in human cancer. Cell Reports 2014;9:1507-1519.
5.
Oberg E, Givant C, Fisk B, Parikh C, Bradley R: Epigenetics in clinical practice: characterizing patient and provider experiences with MTHFR polymorphisms and methylfolate. J Nutrigenet Nutrigenomics 2015;8:137-150.
6.
Panetta JC, Paugh SW, Evans EW: Mathematical modeling of folate metabolism. WIREs Syst Biol Med 2013;5:603-613.
7.
Reed MC, Gamble MV, Hall MN, Nijhout FH: Mathematical analysis of the regulation of competing methyltransferases. BMC Syst Biol 2015;9:69.
8.
Appling DR: Compartmentation of folate-mediated one-carbon metabolism in eukaryotes. FASEB J 1991;5:2645-2651.
9.
Arooj M, Sakkiah S, Cao Gp, Lee KW: An innovative strategy for dual inhibitor design and its application in dual inhibition of human thymidylate synthase and dihydrofolate reductase enzymes. PLoS One 2013;8:e60470.
10.
Hande S, Goswami K, Sharma R, Bhoj P, Jena L, Reddy MV: Targeting folate metabolism for therapeutic option: a bioinformatics approach. Indian J Exp Biol 2015;53:762-766.
11.
Kumar P, Henikoff S, Ng PC: Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009;4:1073-1081.
12.
Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR: A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248-249.
13.
Wang K, Li M, Hakonarson H: ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010;38:e164.
14.
Carr DF, Whiteley G, Alfirevic A, Pirmohamed M: Investigation of inter-individual variability of the one-carbon folate pathway: a bioinformatics and genetic review. Pharmacogenomics J 2009;9:291-305.
15.
Weston AD, Hood L: Systems biology, proteomics and the future of health care: towards predictive, preventive and personalized medicine. J. Proteomics Res 2004;3:179-196.
16.
Li M, Li J, Wei C, Lu Q, Tang X, Erickson SW, MacLeod SL, Hobbs CA: A three-way interaction among maternal and fetal variants contributing to congenital heart defects. Ann Hum Genet 2016;80:20-31.
17.
Wang Q, Lu K, Du H, Zhang Q, Chen T, Shu Y, Hua Y, Zhu L: Association between cytosolic serine hydroxymethyltransferase (SHMT1) gene polymorphism and cancer risk: a meta-analysis. Biomed Pharmacother 2014;68:757-762.
18.
Ji Y, Nordgren KK, Chai Y, Hebbring SJ, Jenkins GD, Abo RP, Peng Y, Pelleymounter LL, Moon I, Eckloff BW, Chai X, Zhang J, Fridley BL, Yee VC, Wieben ED, Weinshilboum RM: Human liver methionine cycle: MAT1A and GNMT gene resequencing, functional genomics, and hepatic genotype-phenotype correlation. Drug Metab Dispos 2012;40:1984-1992.
19.
Fowler B: The folate cycle and disease in humans. Kidney Int Supp 2001;59:S221-S229.
20.
Rai PS, Murali TS, Vasudevan TG, Prasada SK, Bhagavath AK, Pai P, Gopinath PM, Satyamoorthy K: Genetic variation in genes involved in folate and drug metabolism in a south Indian population. Indian J Hum Genet 2011;17:48-53.
21.
de Bree A, van Mierlo LA, Draijer R: Folic acid improves vascular reactivity in humans: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2007;86:610-617.
22.
Jennings BA, Kwok CS, Willis G, Matthews V, Wawruch P, Loke YK: Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis. Pharmacogenet Genomics 2012;22:290-304.
23.
Rai PS, Pai GC, Alvares JF, Bellampalli R, Gopinath PM, Satyamoorthy K: Intraindividual somatic variations in MTHFR gene polymorphisms in relation to colon cancer. Pharmacogenomics 2014;15:349-359.
24.
Cyril C, Rai P, Chandra N, Gopinath PM, Satyamoorthy K: MTHFR gene variants C677T, A1298C and association with Down syndrome: a case-control study from South India. Indian J Hum Genet 2009;15:60-64.
25.
Bellampalli R, Phani NM, Bhat KG, Prasad K, Bhaskaranand N, Guruprasad KP, Rai PS, Satyamoorthy K: Significance of 5,10-methylenetetrahydrofolate reductase gene variants in acute lymphoblastic leukemia in Indian population: an experimental, computational and meta-analysis. Leuk Lymphoma 2015;56:1450-1459.
26.
Nair PS, Vihinen M: VariBench: a benchmark database for variations. Human Mutation 2013;34:42-49.
27.
Adam YY, Liu QR, Li CY, Zhao M, Qu H: Human transporter database: comprehensive knowledge and discovery tools in the human transporter genes. PloS One 2014;9:e88883.
28.
Yang Y, Dong X, Xie B, Ding N, Chen J, Li Y, Zhang Q, Qu H, Fang X: Databases and web tools for cancer genomics study. Genomics Proteomics Bioinformatics 2015;13:46-50.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.